Final Program [International Conference on AIDS (14th: 2002: Barcelona, Spain)]

Poster Exhibitions

Tuesday u

Poster~~~~ Exiiin Tusa Juy

TuPeB4450 Once daily saquinavir-SGC/ritonavir minidosis +
2NRTIs is as effective as saquinavir-SGC
(conventional dose) + 2NRTIs in antiretroviralnaive patients with advanced HIV infection:
results at 24 weeks
J A Hidalgo, R Castillo, J Villena, C Sanchez,
R Salazar (Peru)
TuPeB4451 Efficacy of tenofovir DF (TDF) monotherapy in
chronically HIV-1 infected antiretroviral treatmentnaive patients
M Markowitz, M Louie, N Padte, J Vanderhoeven,
L Zhong, J Flaherty, P Lamy, A Balagtas, D Coakley
(United States)
TuPeB4452 A minority of patients achieve long-term durable
viral suppression with potent antiretroviral
therapy
U Chung, C J Fichtenbaum (United States)
TuPeB4453 Durability and tolerability of the triple NRTI
Regimen abacavir/zidovudine/lamivudine
(ABC/AZT/3TC) based on therapy changes in
antiretroviral therapy-naive patients in the
Frankfurt HIV Cohort
P Gute, B Dauer, TStark, A Haberl, M Bickel,
V Rickerts, B Jennings, S Staszewski (Germany)
TuPeB4454 Antiretroviral response among treatment naive
HIV-i subtype C infected adults in Botswana
W Wester', H Bussmann', A Avalos2, T Peter',
J Makema', A M Reich2, S Ahn', G Sebetso2,
C Onen', P Mazondel, I Thior', M Essex2,
H Moffat', R Marlink2 (Botswana; 2United States)
TuPeB4455 Are there differences between men and women in
their response to HAART?
E H Bileveld', K Squires2
('The Netherlands; 2United States)
TuPeB4456 Efficacy and safety of Indinavir (IDV) 8oo00 mg bid
versus 400oo mg bid combined with ritonavir (RTV)
loo mg bid in naive patients
D Konopnicki, S De Wit, ] P Protto,
B Sommereijns, N Clumeck (Belgium)
TuPeB4457 Triple antiretroviral therapy containing nonnucleoside reverse transcriptase inhibitors in
antiretroviral naive H IV-1-infected patients with
less than 200 CD4 cells/mm3
M Lonca, E Martinez, A Milinkovic, M Garcia,
J L Blanco, J B Perez-Cuevas, J Murillas, F Garcia,
J Mallolas, J M Miro, I M Gatell (Spain)
TuPeB4458 Safety, efficacy and resistance profile under the
new protease inhibitor Lopinavir/ritonavir:
48 week results
E Voigt, J C Wasmuth, D Braitinger, K Schneider,
B Kupfer, R Kaiser, S Mauss, G Schmutz,
1 K Rockstroh (Germany)
TuPeB4459 Long-term efficacy, safety, and tolerability of
nevirapine (NVP)-containing regimens. An
observational study in HIV-1 infected adults
H Eskoetter, T Kaliebe, H Rasokat, H Mielenz
(Germany)
TuPeB446o Safety profile of Tenofovir DF (TDF) in
antiretroviral treatment-experienced patients
from randomized, double-blind, placebocontrolled clinical trials
A Cheng, S Barriere, D F Coakley, S S Chen,
M Wulfsohn, ]J Toole (United States)
TuPeB4461 The efficacy of Tenofovir containing regimen in
salvage therapy
M R Nelson, C Bell, M Bower, A Pozniak,
B G Gazzard (United Kingdom)

TuPeB4462 Successful intensification of antiretroviral therapy
(ART) with abacavir (ABC) in clinical practice
M K Kubota, J Arroyo, A Canas, J Fleming, L You,
S Hessenthaler, J Hernandez (United States)
TuPeB4463 Efficacy and safety of amprenavir (APV)/ritonavir
(RTV) 6oo/loomg BID compared to APV 12oomg
BID in ART-experienced and naive subjects:
ESS400on
J Nadler, J Gathe, R Pollard, G Richmond, Q Liao,
T Lancaster, S Griffith, K Pappa, J Hernandez
(United States)
TuPeB4464 A triple protease inhibitor [PI] salvage regimen of
amprenavir[APV] + saquinavir [SQV] + minidose
ritonavir [r]: steady state [SS] pharmacokinetics
[PK] and initial RNA and CD4 response
A H Corbett, J] JEron, M Diebold, N Rezk, L Troiani,
A D M Kashuba (United States)
TuPeB4465 A low hydroxyurea dose (6oo mg daily) is found
optimal in a randomized, controlled trial (RIGHT
702)
F Lori, R Pollard, P Shalit2, G Blick2, D Peterson,
J Lisziewicz2 (ltaly; 2United States)
TuPeB4466 Indinavir/ritonavir in HIV-infected children
G Jugulete, M I Dragan, M Mardarescu, S Petrea
(Romania)
TuPeB4467 Antiretroviral combination therapy containing
NNRTI (efavirenz). Twenty-four weeks data
C Bussolino M Palumbo, G Calcagno, P De Leo, H
Martines, M Anselmo (Italy)
TuPeB4468 The VireadTM global expanded access program
(EAP): safety and efficacy of tenofovir disoproxil
fumarate (TDF) in antiretroviral treatment (ART)
experienced patients
M Nelson', B Clotet2, C Katlama3, S Follansbee4,
D Cooper5, A Adam6, A Lazzarin7, J Montaner8,
J Lange9, S Van Doren4, R Buffels4, G Choy4,
L Zagury, J Rooney, The Viread Global EAP
Team4 (United Kingdom; 2Spain; 3France; 4United
States; 5Australia; 6Germany; 7ltaly; 8Canada;
9The Netherlands)
TuPeB4469 Prospective trial with CBV +IDV in West Africa
Y Diop', TA Toni'., D Bonard', F 0 Ba-Gomis',
E Sia', V K Nguyen2, H Chenal' (Cote d'lvoire;
2Canada)
TuPeB447o Genetic correlates of virological response to an
Indinavir (IDV/CRIXIVAN)-Ritonavir (RTV) regimen
in Protease Inhibitor (PI) experienced patients
with early virological failure: Protocol 107
J Nadler H Katner, H Wilson, TS Finn, S Rawlins,
E Jensen, R Zeldin (United States)
TuPeB4471 Comparison of efavirenz and nevirapine in
antiretroviral naive and pretreated patients in a
real world setting
M Hartmann A Rump, I Brust, D Schuster,
F Mosthaf, M Procacchianti, H Klinker, D Petzoldt
(Germany)
TuPeB4472 Resistance testing in HIV-1 infected patients
treated with indinavir/ritonavir 800mg/ioomg
BID after at least one protease inhibitor-based
therapy failure
R Boulmd', S De Wit2, C Necsoi2, B Sommereijns2
I C Schmit', N Clumeck2 (Luxembourg; 2Belgium)
TuPeB4473 A randomized study of treatment simplification
with nevirapine (NVP) or efavirenz (EFV) in
patients responding to a protease inhibitor (PI)
based combination
P Patterson C Zala, A Krolewiecki, C Ochoa,

A Gun, S Kaufman, H Perez, P Cahn (Argentina)

Tuesday

XIV International AIDS Conference BARCELONA - JULY 7-12

95